A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

← catalyst calendar

NCT07492680 · readout in 726 d

Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

260estimated

Sites

Countries

Belgium, Canada, China +10

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-07-27

actual

When the study began enrolling

Primary completion

2028-08-15

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2032-05-20

estimated

The whole study's end, after follow-up

First posted

2026-03-25

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-30

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Solid Tumors

Interventions

Drug: BMS-986504 — also filed as MRTX1719, Navlimetostat
Drug: Daraxonrasib — also filed as RMC 6236
Drug: Nivolumab + Relatlimab FDC
Drug: Temozolomide
Drug: Pumitamig — also filed as BNT327
Drug: Pemetrexed
Drug: Carboplatin
Drug: Nab-paclitaxel
Drug: Gemcitabine
Drug: Paclitaxel